Accelerating Medicines Partnership<sup>®</sup> Schizophrenia (AMP<sup>®</sup>SCZ): developing tools to enable early intervention in the psychosis high risk state

Brady, Linda S.; Larrauri, Carlos A.

doi:10.1002/wps.21038

Cited by 26 publications

(17 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The consortia approach can allow to collect large samples, as in the Function Biomedical Informatics Research Network (FBIRN), the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP), the Social Processes Initiative in Neurobiology of the Schizophrenia(s) (SPINS), the NAPLS and the ProNET studies, and the ongoing Accelerating Medicines Partnership (AMP) -Schizophrenia (SCZ) Programme [375][376][377][378][379] . In these projects, the focus is making the study parameters as similar as possible, so that the samples are homogeneous, the clinical assessments are the same across the whole sample, and the imaging techniques are prescribed prior to data collection to reduce site differences.…”

Section: Methodological Considerations and Advancesmentioning

confidence: 99%

Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions

Voineskos,

Hawco,

Neufeld

et al. 2024

World Psychiatry

View full text Add to dashboard Cite

Functional neuroimaging emerged with great promise and has provided fundamental insights into the neurobiology of schizophrenia. However, it has faced challenges and criticisms, most notably a lack of clinical translation. This paper provides a comprehensive review and critical summary of the literature on functional neuroimaging, in particular functional magnetic resonance imaging (fMRI), in schizophrenia. We begin by reviewing research on fMRI biomarkers in schizophrenia and the clinical high risk phase through a historical lens, moving from case‐control regional brain activation to global connectivity and advanced analytical approaches, and more recent machine learning algorithms to identify predictive neuroimaging features. Findings from fMRI studies of negative symptoms as well as of neurocognitive and social cognitive deficits are then reviewed. Functional neural markers of these symptoms and deficits may represent promising treatment targets in schizophrenia. Next, we summarize fMRI research related to antipsychotic medication, psychotherapy and psychosocial interventions, and neurostimulation, including treatment response and resistance, therapeutic mechanisms, and treatment targeting. We also review the utility of fMRI and data‐driven approaches to dissect the heterogeneity of schizophrenia, moving beyond case‐control comparisons, as well as methodological considerations and advances, including consortia and precision fMRI. Lastly, limitations and future directions of research in the field are discussed. Our comprehensive review suggests that, in order for fMRI to be clinically useful in the care of patients with schizophrenia, research should address potentially actionable clinical decisions that are routine in schizophrenia treatment, such as which antipsychotic should be prescribed or whether a given patient is likely to have persistent functional impairment. The potential clinical utility of fMRI is influenced by and must be weighed against cost and accessibility factors. Future evaluations of the utility of fMRI in prognostic and treatment response studies may consider including a health economics analysis.

show abstract

Section: Methodological Considerations and Advancesmentioning

confidence: 99%

Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions

Voineskos,

Hawco,

Neufeld

et al. 2024

World Psychiatry

View full text Add to dashboard Cite

show abstract

“…A limitation of this study is that, in order to minimize participant burden, some factors that might be relevant to basic self‐disturbance, such as certain psychological, social and genetic factors (Sass et al, 2018), are not assessed. However, approximately 80% of SNAP participants are also participating in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) (Brady & Larrauri, 2023), a large international observational study with a comprehensive battery, including measures of social risk factors and stress exposure. These extra variables may be included in some SNAP study data analysis.…”

Section: Sample Size Calculation and Statistical Methodsmentioning

confidence: 99%

The self, neuroscience and psychosis study: Testing a neurophenomenological model of the onset of psychosis

Krcmar,

Wannan,

Lavoie

et al. 2023

Early Intervention Psych

View full text Add to dashboard Cite

AimBasic self disturbance is a putative core vulnerability marker of schizophrenia spectrum disorders. The primary aims of the Self, Neuroscience and Psychosis (SNAP) study are to: (1) empirically test a previously described neurophenomenological self‐disturbance model of psychosis by examining the relationship between specific clinical, neurocognitive, and neurophysiological variables in UHR patients, and (2) develop a prediction model using these neurophenomenological disturbances for persistence or deterioration of UHR symptoms at 12‐month follow‐up.MethodsSNAP is a longitudinal observational study. Participants include 400 UHR individuals, 100 clinical controls with no attenuated psychotic symptoms, and 50 healthy controls. All participants complete baseline clinical and neurocognitive assessments and electroencephalography. The UHR sample are followed up for a total of 24 months, with clinical assessment completed every 6 months.ResultsThis paper presents the protocol of the SNAP study, including background rationale, aims and hypotheses, design, and assessment procedures.ConclusionsThe SNAP study will test whether neurophenomenological disturbances associated with basic self‐disturbance predict persistence or intensification of UHR symptomatology over a 2‐year follow up period, and how specific these disturbances are to a clinical population with attenuated psychotic symptoms. This may ultimately inform clinical care and pathoaetiological models of psychosis.

show abstract

“…The PSYCHS is currently in use in the 42-site AMP SCZ (Brady et al, 2023) observational study (https://www.ampscz.org). As of December 2022, more than 100 interviewers had been trained and certified, more than 100 participants had undergone assessment with the Screening Instrument, and five coordinated weekly consensus calls were ongoing.…”

Section: Current Usementioning

confidence: 99%

Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

Woods

Parker

Kerr

et al. 2023

Preprint

View full text Add to dashboard Cite

Aim: To harmonize two ascertainment and severity rating instruments commonly used for the clinical high risk syndrome for psychosis (CHR-P): the Structured Interview for Psychosis-risk Syndromes (SIPS) and the Comprehensive Assessment of At-Risk Mental States (CAARMS). Methods: The initial workshop is described in the companion report from Addington et al. After the workshop, lead experts for each instrument continued harmonizing attenuated positive symptoms and criteria for psychosis and CHR-P through an intensive series of joint videoconferences. Results: Full harmonization was achieved for attenuated positive symptom ratings and psychosis criteria, and partial harmonization for CHR-P criteria. The semi-structured interview, named Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS (PSYCHS), generates CHR-P criteria and severity scores for both CAARMS and SIPS. Conclusion: Using the PSYCHS for CHR-P ascertainment, conversion determination, and attenuated positive symptom severity rating will help in comparing findings across studies and in meta-analyses.

show abstract

Accelerating Medicines Partnership^® Schizophrenia (AMP^®SCZ): developing tools to enable early intervention in the psychosis high risk state

Cited by 26 publications

References 6 publications

Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions

Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions

The self, neuroscience and psychosis study: Testing a neurophenomenological model of the onset of psychosis

Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

Contact Info

Product

Resources

About

Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ): developing tools to enable early intervention in the psychosis high risk state

Cited by 26 publications

References 6 publications

Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions

Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions

The self, neuroscience and psychosis study: Testing a neurophenomenological model of the onset of psychosis

Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

Contact Info

Product

Resources

About

Accelerating Medicines Partnership^® Schizophrenia (AMP^®SCZ): developing tools to enable early intervention in the psychosis high risk state